Stockchase Opinions

Bruce Cooper Stressgen Biotechnologies Corp SSB-T WEAK BUY May 17, 2002

In the final stage of their clinical trials. Will be a couple of years before you know if the product works.
$4.500

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY
They are far enough into their trials that investors are now paying more attention. Relatively cheap. Management is OK.
BUY ON WEAKNESS
A speculative stock. Has to move through the regulatory gateway. Meets a lot of technical resistance at the $1.81 level. Try to pick up near its support level of $1.25.
DON'T BUY
On their watch list. Lost a lot of maney last year.
BUY
Very volatile. Developing a product for HBV (a sexually transmitted disease), which has a large market. In phase two. Has a partnership with Roach and has enough cash to probably last into 2005.
DON'T BUY
Have restructured and will need more money.
TRADE
A field that you have to be really wary of. Many of them have a very high burn rate. Although their trials were fast tracked, this does not necessarily mean continued success.
TOP PICK
Holds this stock personally. Risky could double.
PAST TOP PICK
(A Top Pick June 14/04. Down 56%.) They continue to lose money. They'll have to get something through their pipeline quickly that deals with cancer. Doesn't look good.
DON'T BUY
Trying to raise $50 million which is equivalent/more than their entire market cap.
DON'T BUY
A lottery ticket! The company has gone into orphan status. Have disappointed investors many, many times. They keep needing money. Very risky.